Redstone’s Post

🔔 HIVEN® DEVICE CLEARED FOR CE MARK 🔔 We’re thrilled to announce that MARGINUM® HIVEN® has received EU MDR certification, marking a major milestone in advancing neurosurgical treatment of brain cancer. 👉 https://lnkd.in/d269DqTR HIVEN® is the first intraoperative system in Europe to enable quantitative tumour margin detection from aspirated tissues with unprecedented accuracy, supporting more intelligent and precise surgical decision-making. With the CE mark, HIVEN® is now cleared for clinical use across the EU and other CE-recognising markets – paving the way for safer surgeries and better neurosurgical outcomes. ✨ Key Highlights 🧠 Objective tumour margin analysis during surgery 🔬 Fluorescence detection without limitations from visual obstructions  ⚡ Continuous feedback in real-time throughout the operation  🏥 Seamlessly integrates with standard OR workflows Developed in close collaboration with leading neurosurgeons and key opinion leaders, HIVEN® represents a new standard of precision for oncological surgery – decreasing postoperative complications and improving patient safety. We’re now launching a limited clinical release with select European surgical centres, accelerating the adoption of the MARGINUM® aspirate tissue monitoring surgical technique in the operating room. Nostetta Ventures, Redstone, Almaral, Lynx Financial 德石资本, Oslo University Hospital, Tampere University Hospital, Kuopio University Hospital (KUH) - Kuopion yliopistollinen sairaala (KYS), University of Eastern Finland, Business Finland, Kuopio Health, Mediplast AB #neurosurgery #medtechinnovation #CEmark #marginum